Welcome to our dedicated page for Day One Biopharmaceuticals SEC filings (Ticker: DAWN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Day One Biopharmaceuticals filings document the company's transition from a Nasdaq-listed oncology biopharmaceutical issuer to an acquired company with Exchange Act deregistration filings. The record includes Form 25 removal of DAWN common stock from Nasdaq and Form 15 certification covering termination of registration or suspension of reporting duties after the acquisition.
Day One's 8-K filings report material agreements, tender-offer and merger-related events, shareholder voting and governance matters, capital-structure disclosures, and financial-statement exhibits. Other disclosures cover OJEMDA (tovorafenib), U.S. product revenue reporting, Ipsen's ex-U.S. commercialization rights, and clinical or regulatory updates for pediatric low-grade glioma and rare-cancer programs.
Day One Biopharmaceuticals director Saira Ramasastry disposed of all reported equity interests in connection with the company’s cash merger with Servier. The filing shows 40,485 shares of Common Stock, 15,000 restricted stock units and multiple stock option grants were surrendered to the issuer on April 23, 2026.
Under the merger, each Day One share was purchased or converted into the right to receive $21.50 in cash, and each option or RSU was canceled for a cash payment based on this price, less any applicable exercise price and taxes. Following these transactions, the Form 4 lists no remaining shares or options for the reporting person.
Day One Biopharmaceuticals director John A. Josey disposed of his equity in connection with the company’s cash merger with Servier. Following the April 23, 2026 closing, his 72,292 shares of common stock were converted into cash at $21.50 per share under the merger terms.
His 15,000 restricted stock units and multiple fully vested stock option grants, covering tens of thousands of shares with exercise prices including $7.01 and $8.99, were canceled and converted into cash based on the merger consideration. After these issuer dispositions, the Form 4 shows no remaining common stock or derivative holdings.
Day One Biopharmaceuticals director Garland J. Scott reported dispositions of equity awards to the company in connection with its cash merger with Servier. On April 23, 2026, 15,000 restricted stock units and several stock option grants covering 22,500, 32,335, 37,500, 28,700 and 48,072 shares of common stock were disposed of to the issuer.
Under the merger, each common share was purchased or converted into the right to receive $21.50 in cash per share. At the merger’s effective time, all stock options and RSUs, which had become fully vested immediately beforehand, were canceled and converted into cash equal to the $21.50 merger consideration, or for options the $21.50 amount minus the applicable exercise price, less taxes.
Day One Biopharmaceuticals, Inc. director Habib J. Dable reports dispositions of equity awards back to the company tied to its cash merger. A completed merger with Servier entities converted Day One into a wholly owned subsidiary, with each common share purchased or converted for $21.50 per share in cash.
Immediately before the merger’s effective time, all unvested stock options and restricted stock units became fully vested. At closing, 15,000 RSUs and multiple stock option grants were canceled and converted into cash equal to the Merger Consideration, or for options the spread between $21.50 and each grant’s exercise price, less applicable taxes.
Day One Biopharmaceuticals director William Grossman reported the cancellation of equity awards in connection with the company’s cash merger with Servier entities. On April 23, 2026, he disposed to the issuer of 15,000 restricted stock units and three stock option grants covering 22,500, 32,335 and 66,660 shares of Common Stock.
Footnotes explain that, upon closing of the merger at $21.50 per share in cash, all outstanding unvested stock options and RSUs became fully vested, then each option and RSU was canceled and converted into the right to receive cash equal to the merger consideration (or, for options, the merger consideration minus the applicable exercise price), less withholding taxes. Following these transactions, the filing shows no remaining derivative holdings.
Day One Biopharmaceuticals director Garry A. Nicholson reported returning equity awards to the company in connection with its merger with Servier Pharmaceuticals LLC. On April 23, 2026, he disposed of 15,000 restricted stock units and multiple stock option grants back to the issuer.
Footnotes explain that, upon the merger closing at an offer price of $21.50 per share, all outstanding stock options and restricted stock units were fully vested, then canceled and converted into cash. For stock options, the cash amount equaled the difference between the $21.50 merger consideration and each option’s exercise price, less applicable taxes, leaving no remaining derivative holdings from these awards.
Day One Biopharmaceuticals, Inc. has been acquired by Servier under a merger that closed on April 23, 2026, with common stockholders receiving $21.50 per share in cash.
As part of the closing, Chief Commercial Officer Lauren Merendino disposed of 60,157 shares of common stock and all outstanding equity awards, including multiple restricted stock unit and stock option grants, through issuer dispositions. These awards were canceled and converted into cash based on the $21.50 per-share Merger Consideration, or, for options, the cash value of the spread over their exercise prices, less applicable taxes. Following these transactions, the filing shows Merendino with no remaining common shares or derivative equity holdings in the company.
Day One Biopharmaceuticals, Inc. notified the Nasdaq Stock Market LLC of the removal of its Common Stock from listing and registration under Section 12(b) via Form 25. The Exchange states it complied with 17 CFR 240.12d2-2 and the issuer complied with the Exchange's rules governing voluntary withdrawal.
Day One Pharmaceuticals, Inc. has filed post-effective amendments to withdraw and deregister all securities remaining unsold under its Form S-3 registration statements No. 333-274521 and No. 333-281822 after completing a merger that made the company a wholly owned subsidiary of Servier.
The filing states the termination of any and all offerings under the Registration Statements and removes from registration, by post-effective amendment, any securities that remained unsold as of April 23, 2026, pursuant to the Merger Agreement dated March 6, 2026.
Day One Pharmaceuticals, Inc. filed Post-Effective Amendment No. 1 to two Form S-3 registration statements to terminate those registration statements and remove any unsold securities, effective April 23, 2026. The filing states the termination follows the closing of a merger under the Agreement and Plan of Merger dated March 6, 2026, in which Servier Detroit Inc. merged with and into Day One and Day One became a wholly owned subsidiary of Servier Pharmaceuticals LLC.
The amendments state that, after giving effect to the post-effective amendments, there will be no remaining securities registered under the Registration Statements (Registration Nos. 333-274521 and 333-281822).